O
Olga Goloubeva
Researcher at University of Maryland, Baltimore
Publications - 159
Citations - 9571
Olga Goloubeva is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Cancer & Aromatase. The author has an hindex of 48, co-authored 149 publications receiving 8657 citations. Previous affiliations of Olga Goloubeva include University of Maryland Medical Center & University of Maryland Marlene and Stewart Greenebaum Cancer Center.
Papers
More filters
Journal ArticleDOI
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P. Rapoport,Edward A. Stadtmauer,Gwendolyn Binder-Scholl,Olga Goloubeva,Dan T. Vogl,Simon F. Lacey,Ashraf Badros,Alfred L. Garfall,Brendan M. Weiss,Jeffrey Finklestein,Irina Kulikovskaya,Sanjoy K. Sinha,Shari Kronsberg,Minnal Gupta,Sarah Bond,Luca Melchiori,Joanna E. Brewer,Alan D. Bennett,Andrew B. Gerry,Nicholas J. Pumphrey,Daniel Williams,Helen K. Tayton-Martin,Lilliam Ribeiro,Tom Holdich,Saul Yanovich,Nancy M. Hardy,Jean A. Yared,Naseem Kerr,Sunita Philip,Sandra Westphal,Don L. Siegel,Bruce L. Levine,Bent K. Jakobsen,Michael Kalos,Carl H. June +34 more
TL;DR: NY-ESO-1–LAGE-1 TCR–engineered T cells were safe, trafficked to marrow and showed extended persistence that correlated with clinical activity against antigen-positive myeloma, according to the expected mechanism of action of the transferred T cells.
Journal ArticleDOI
Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors
Ashraf Badros,Dianna Weikel,Andrew Salama,Olga Goloubeva,Abraham Schneider,Aaron P. Rapoport,Robert G. Fenton,Natalie Gahres,Edward A. Sausville,Robert A. Ord,Timothy F. Meiller +10 more
TL;DR: ONJ appears to be time-dependent with higher risk after long-term use of bisphosphonates in older MM patients often after dental extractions, and trials addressing the benefits/risks of continuing bisph phosphonate therapy are needed.
Journal Article
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
Richard Leblanc,Laurence Catley,Teru Hideshima,Suzanne Lentzsch,Constantine S. Mitsiades,Nicholas Mitsiades,Donna Neuberg,Olga Goloubeva,Christine S. Pien,Julian Adams,Deepak Gupta,Paul G. Richardson,Nikhil C. Munshi,Kenneth C. Anderson +13 more
TL;DR: It is demonstrated that PS-341 has significant in vivo antimyeloma activity at doses that are well tolerated in a murine model, confirming the in vitro data and further supporting the early clinical promise of PS- 341 to overcome drug resistance and improve patient outcome.
Journal ArticleDOI
Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial
Marshall R. Posner,Jochen H. Lorch,Olga Goloubeva,Ming Tan,Lisa M. Schumaker,Nicholas J. Sarlis,Robert I. Haddad,Kevin J. Cullen +7 more
TL;DR: HPV+ OPC has a different biology compared with HPV- OPC; 5-year OS, PFS, and local-regional control are unprecedented; these results support the possibility of selectively reducing therapy and long-term morbidity in HPV+ O PC while preserving survival and approaching HPV- disease with more aggressive treatment.
Journal ArticleDOI
Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis.
Shawna L. Palmer,Olga Goloubeva,Wilburn E. Reddick,John O. Glass,Amar Gajjar,Larry E. Kun,Thomas E. Merchant,Raymond K. Mulhern +7 more
TL;DR: The hypothesis that MB patients demonstrate a decline in IQ values because of an inability to acquire new skills and information at a rate comparable to their healthy same-age peers, as opposed to a loss of previously acquired information and skills is supported.